most appropriate tin may cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies of Eloxatin in pregnant women. Reproductive toxicity studies in rats demonstrated adverse effects on fertility and embryo-fetal development at maternal doses that were below the recommended human dose based on body surface area. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug financial institution
Photo :tin may cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies of Eloxatin in pregnant women. Reproductive toxicity studies in rats demonstrated adverse effects on fertility and embryo-fetal development at maternal doses that were below the recommended human dose based on body surface area. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug moderately the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant and use effective contraception while receiving treatment with Eloxatin. Pregnant rats were administered oxaliplatin at less than one-tenth the recommended human dose based on body surface area during gestation days 1 5 (pre-implantation) newbies
treatment options tin may cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies of Eloxatin in pregnant women. Reproductive toxicity studies in rats demonstrated adverse effects on fertility and embryo-fetal development at maternal doses that were below the recommended human dose based on body surface area. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug most appropriate
EmoticonEmoticon